Skip to content

Released Jan 31, 2023, before the open

10-K filed Feb 23, 2023, 54 days after period end · 0000078003-23-000024

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$15.75Bderived−2.7% vs Q4 2021−30.4% vs Q3 2022
Net Income$4.99Bderived+47.2% vs Q4 2021−42.0% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$8,582,000,000+45.1%
Free Cash Flowderived$7,581,000,000+54.3%
Margins · derived
Net margin31.7%+10.7 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$15.75B$16.19B$11.43B$1.84B
Net Income$4.99B$3.39B$846.00M-$584.00M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR